<DOC>
	<DOCNO>NCT02923986</DOCNO>
	<brief_summary>The primary objective Phase 1b study determine dose-limiting toxicity ( DLT ) maximal tolerate dose ( MTD ) BP1001 Dasatinib ( Das ) patient Philadelphia chromosome positive ( Ph+ ) Chronic Myelogenous Leukemia ( CML ) accelerate blast phase . The primary objective Phase IIa study ass efficacy combination BP1001 Das patient Ph+ CML .</brief_summary>
	<brief_title>Clinical Trial BP1001 ( Liposomal Grb2 Antisense Oligonucleotide ) Combination With Dasatinib Patients With Ph + CML</brief_title>
	<detailed_description>The Grb2 gene map human chromosome region 17q22-qter , region duplicate leukemias solid tumor , may result increase copy number Grb2 gene product . As Grb2 important transformation murine hematopoietic cell , proliferation human leukemia cell express high level oncogenic tyrosine kinase , inhibition Grb2 may significant impact natural history leukemia . The study drug ( BP1001 ) may able inhibit cell make Grb-2 . Researchers hope without protein , leukemia cell die . Dasatinib ( Das ) well establish therapeutic regimen treatment Ph+ CML patient accelerate blast phase . Researchers hope combination BP1001 Das provide benefit CML patient accelerate blast phase , typically respond front-line treatment , imatinib . This Phase Ib/IIa , multicenter , study BP1001 combination Das participant Ph+ CML accelerate blast phase . This trial utilize single arm , open label design ass safety profile , DLT , MTD , PK , efficacy BP1001 combination Das . Phase Ib portion study : The Phase Ib study employ open-label , sequential , dose-escalation design ass safety , tolerability toxicity , tumor response anti-leukemic activity . A standard `` 3+3 '' design use successive cohort patient CML treat BP1001 MTD ( high test dose [ HTD ] MTD define ) 1 level MTD ( HTD ) combination fix dose Das characterize safety biological effect , well identify recommended Phase IIa dose . Phase IIa portion study : The Phase IIa study open-label , single-dose level study . All participant eligible receive treatment study receive dose level BP1001 ( HTD 1 level HTD ) determine Phase Ib study Das ( 140 mg ) . There randomization study . The Phase IIa study compare efficacy BP1001 combination Das historical response rate document Das alone , evaluate PK BP1001 , give alone combination Das . Approximately 40 evaluable participant receive combination BP1001 Das Phase IIa .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Adults ≥18 year age 2 . Females must nonchildbearing potential , surgically sterile , postmenopausal , practice adequate method contraception study 30 day last dose study drug Das 3 . Males must agree use adequate method contraception study least 30 day last dose study drug Das 4 . Histologically documented diagnosis Ph+ CML , accelerate blast phase . One follow parameter require meet criterion accelerate CML : Blasts Peripheral Blood Bone Marrow ≥15 % ( either myeloid lymphoid blast ) Promyelocytes Blasts Peripheral Blood Bone Marrow ≥30 % PB BM basophils ≥20 % Thrombocytopenia &lt; 100 x 103/ml , result therapy Cytogenetic clonal evolution Blast phase define ≥30 % blast peripheral blood bone marrow , presence extramedullary disease , except liver spleen . 5 . Adequate hepatic renal function define : 1 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 time upper limit normal ( ULN ) ; 2 . Total bilirubin ≤1.5 time ULN ; 3 . Estimated glomerular filtration rate ( eGFR ) least 50 ml/min ; Cockcroft Gault formula utilized determine eGFR blood urea nitrogen ( BUN ) creatinine test perform baseline . The combination eGFR serum creatinine BUN use evaluate patient 's renal function safety assurance . 6 . Documented Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 7 . Recovered effect prior surgery , radiotherapy , antineoplastic treatment ( exception alopecia ) , base Investigator assessment 8 . Willing able provide write informed consent 1 . Patients T315I mutation exclude , response analyze separately . 2 . Another primary malignancy CML within past 2 year except nonmelanoma skin cancer , carcinoma situ cervix . 3 . Known , active leptomeningeal leukemia require intrathecal therapy . NOTE : Patients history CNS disease may allow participate base least 2 consecutive document , negative spinal fluid assessment prior Screening 4 . Isolated extramedullary leukemia without also meet bone marrow criterion leukemia 5 . Receipt anticancer therapy within 14 day start BP1001 , exception hydroxyurea anagrelide , TKI ( within 2 day ) 6 . Uncontrolled active , untreated , progressive infection 7 . Receipt investigational agent within 14 day 5 halflives start BP1001 8 . Females pregnant , test positive pregnancy , breastfeed Screening period , intend become pregnant breastfeed course study within 30 day last dose study drug 9 . Prior exposure BP1001 10 . Patients history intolerance Das Das might appropriate 11 . Serious intercurrent medical psychiatric illness , opinion Investigator , would interfere ability participant complete study 12 . Active/chronic hepatitis B infection ( base positive surface antigen [ HBsAg ] ) , hepatitis C infection ( base positive antibody [ HCV Ab ] ) , human immunodeficiency virus ( HIV1 HIV2 , base positive antibody ) 13 . Presence concurrent condition , opinion Investigator and/or Medical Monitor , may compromise participant 's ability tolerate study treatment interfere aspect study conduct interpretation result . This include , limited , unstable uncontrolled angina , New York Heart Association ( NYHA ) class III IV congestive heart failure , uncontrolled sustain hypertension , clinically significant cardiac dysrhythmia clinically significant ECG abnormality ( eg , QTcF &gt; 470 msec ) 14 . Within past 6 month , follow : pleural effusion , myocardial infarction , unstable angina pectoris , coronary/peripheral artery bypass graft , cerebrovascular accident transient ischemic attack 15 . Uncontrolled seizure disorder ( ie , seizure within past 2 month ) . 16 . Unable unwilling communicate cooperate Investigator follow protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Liposomal Grb-2 treatment Ph+ CML</keyword>
	<keyword>Liposomal Grb-2 Das Ph+ CML</keyword>
</DOC>